Sorrento Therapeutics (SRNE)
Sector: | Health Care |
Super Investor Stats: | |
Ownership count: | 0 |
Ownership rank: | -- |
% of all portfolios: | 0% |
History | Portfolio Manager | Activity ▼ | Share change | % change to portfolio | |
Q2  2023 | |||||
≡ | Howard Marks - Oaktree Capital Management | Sell 100.00% | 134,000 | 0.00 | |
Q2  2022 | |||||
≡ | Howard Marks - Oaktree Capital Management | Reduce 10.67% | 16,000 | 0.00 | |
Q4  2021 | |||||
≡ | Howard Marks - Oaktree Capital Management | Add 11.94% | 16,000 | 0.00 | |
Q2  2021 | |||||
≡ | Howard Marks - Oaktree Capital Management | Reduce 58.13% | 186,000 | 0.03 | |
Q1  2021 | |||||
≡ | Howard Marks - Oaktree Capital Management | Buy | 320,000 | 0.05 | |
Q4  2020 | |||||
≡ | Lee Ainslie - Maverick Capital | Sell 100.00% | 27,838 | 0.01 | |
Q3  2020 | |||||
≡ | Lee Ainslie - Maverick Capital | Buy | 27,838 | 0.01 | |
≡ | David Katz - Matrix Asset Advisors | Sell 100.00% | 50,000 | 0.06 | |
≡ | Howard Marks - Oaktree Capital Management | Sell 100.00% | 100,500 | 0.02 | |
Q2  2020 | |||||
≡ | Howard Marks - Oaktree Capital Management | Buy | 100,500 | 0.02 | |
Q1  2020 | |||||
≡ | David Katz - Matrix Asset Advisors | Buy | 50,000 | 0.02 |
* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.